ANIX Company Profile and Key Details

Q: Who are the executives of ANIX?

Dr. Pamela D. Garzone Ph.D.Chief Devel. Officer & Chair Breast Cancer Clinical Advisory BoardDr. Amit Kumar Ph.D.Chairman & Chief Executive OfficerMr. Michael J. Catelani CPA, MBAPres, Chief Operating Officer, Chief Financial Officer & Corporation Sec.Mr. John RoopSenior Vice President of Engineering

NASDAQ : ANIX

Anixa Biosciences

$3.37

0.07+2.12%

Open: 2:55 PM

66.08

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Anixa Biosciences, Inc. (ANIX) stock surged +2.12%, trading at $3.37 on NASDAQ, up from the previous close of $3.30. The stock opened at $3.31, fluctuating between $3.28 and $3.42 in the recent session.

Stock Snapshot

3.3

Prev. Close

110.92M

Market Cap

3.2817

Day Low

-9.91

P/E Ratio

-0.34

EPS (TTM)

-0.21

Cash Flow per Share

3.31

Open

32.91M

Number of Shares

3.42

Day High

94.7%

Free Float in %

0.78

Book Value

106.79K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	3.23	3.33	3.18	3.30	407.85K
Dec 17, 2025	3.60	3.62	3.21	3.27	630.1K
Dec 16, 2025	3.30	3.64	3.25	3.57	631.67K
Dec 15, 2025	3.59	3.60	3.25	3.26	748.18K
Dec 12, 2025	5.00	5.10	3.52	3.58	2.15M
Dec 11, 2025	5.16	5.20	4.55	4.80	583.85K
Dec 10, 2025	5.10	5.21	4.92	5.13	444.76K
Dec 09, 2025	5.33	5.46	4.90	5.06	464.49K
Dec 08, 2025	4.92	5.23	4.88	5.22	600.57K
Dec 05, 2025	4.76	4.90	4.67	4.79	183.63K
Dec 04, 2025	4.82	4.85	4.64	4.74	202.47K
Dec 03, 2025	4.67	4.91	4.46	4.85	578.4K
Dec 02, 2025	4.41	4.54	4.20	4.20	119.01K
Dec 01, 2025	4.54	4.57	4.39	4.40	128.08K
Nov 28, 2025	4.70	4.70	4.55	4.59	87.59K
Nov 26, 2025	4.32	4.70	4.26	4.64	209.86K
Nov 25, 2025	4.35	4.38	4.15	4.32	90.45K
Nov 24, 2025	4.34	4.45	4.26	4.35	105.23K
Nov 21, 2025	4.38	4.49	4.25	4.34	144.95K
Nov 20, 2025	4.41	4.59	4.33	4.40	233.1K

Contact Details

San Jose, CA 95118

United States

https://www.anixa.com 408 708 9808

About Company

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Stock Peers

ARGX

7.94+0.94%

argenx SE$854.99 REGN

19.25+2.57%

Regeneron Pharmaceuticals, Inc.$767.96 MDGL

46.61+8.56%

Madrigal Pharmaceuticals, Inc.$591.02 UTHR

10.13+2.00%

United Therapeutics Corporation$517.13 VRTX

8.82+1.97%

Vertex Pharmaceuticals Incorporated$456.20 ALNY

4.19+1.06%

Alnylam Pharmaceuticals, Inc.$400.23 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

3.66001+1.36%

Praxis Precision Medicines, Inc.$272.92 KRYS

7.43+3.18%

Krystal Biotech, Inc.$240.80 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Anixa Biosciences, Inc. (NASDAQ:ANIX) closed at $3.37 USD, gaining $0.07 (2.12%) from the previous close of $3.30. The stock is currently mid-range between its 52-week high and low $2.07 and $5.46. With a market capitalization of about $110.92 million, Anixa Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.50). Key stats such as the average daily volume over the past year has been around 318.05 thousand shares, volume is running light vs its 52-week average. Headquartered in San Jose, CA, Anixa Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Amit Kumar, the company employs approximately 5 people and listed since October 07, 1983. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -22.94%, SMA50 -22.43%, SMA200 -1.42%). The stock’s 14-day RSI is 36.73 (weak momentum), while the ATR of 0.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -39.52% below its high and over 59.42% above its low. Average 10-day trading volume of 913.38 thousand shares is significantly above the 3-month average of 286.68 thousand, indicating heightened recent market interest.

Valuation Metrics

Anixa Biosciences, Inc. trades at a P/E ratio of -12.1, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.46 trading at moderately above to book value. The P/FCF stands at -15.87, also below market averages.

Dividend & Fair Value

Anixa Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.03. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Anixa Biosciences, Inc. generated EPS of -$0.34 over the past year. Five-year average earnings growth is 7.73%. Wall Street analysts project EPS growth of 4.76% annually over the next five years. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$15.62. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $7.00. The high target offers 203.03% upside. The low target suggests 112.12% downside. The mean target is $9.36. This offers 183.64% upside. Anixa Biosciences, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended September 10, 2025, missed forecasts by -30.0%. The prior quarter beat by -10.0%. Over the last six quarters, Apple has recorded several small beats. These include -9.09% in June 04, 2024.

Shareholding & Insider Activity

Anixa Biosciences, Inc. has 32.92 million shares outstanding. The public float is 31.12 million shares, elevated short interest at 1.76% of float. This equals 565.27 thousand shares. The short ratio is 3.62 days. Institutional investors hold 17.84% of the float. Insiders own 5.43%. Titterton Lewis H jr holds 953.33 thousand shares, KUMAR AMIT has 579.92 thousand shares and JOHNSON BRUCE F has 419.12 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Anixa Biosciences has not generated any revenue. Returns are negative, with ROA at -49.19% and ROE at -51.58%.
On valuation metrics, Anixa Biosciences trades at a P/E of -12.10, P/S of 0.00 and P/B of 6.46. The current ratio is 8.45 and quick ratio is 8.45. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -11193.33 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -32.14.

Quarterly Financial Highlights

For the quarter ended Oct 31, 2024, Anixa Biosciences posted revenue of $0.00, down slightly from $210.00K in the prior quarter. Operating income was - $13.83M (margin 0.0%). Net income was- $12.55M (EPS - $0.39).
The company ended the quarter with $23.84M in cash and short-term investments, a total debt of $175.00K, and net debt of - $740.00K. Total assets were $25.52M, with equity of $23.37M. Financials further reflected weakness, with operating cash flow of - $6.21M, free cash flow of - $6.21M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Anixa Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.52%, with price expected at $3.35 by January 02, 2026, within a range of $2.75 to $3.89 3-Month Outlook: Projected rise of 28.48%, reaching $4.24 by March 19, 2026, with a range of $4.05 to $4.43. 1-Year Outlook: Projected gain of 612.12%, with price at $23.50 by December 18, 2026, within a range of $23.22 to $29.11.

Key Takeaways

Anixa Biosciences, Inc. (NASDAQ:ANIX) shares are up 42.24% year-to-date currently trading near 52-week highs band. Short-term momentum has been flat over the last quarter, despite recent volatility. Valuation shows Anixa Biosciences, Inc. trading at a premium to the broader market with a P/E of -12.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.91, suggesting 200.3% upside. Our AI forecast model points to short-term strength (1.52% over two weeks), a medium-term rise (28.48% over three months), and a longer-term gain (612.12% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Anixa Biosciences, Inc. (ANIX) stock price?

Anixa Biosciences, Inc. (NASDAQ: ANIX) stock price is $3.37 in the last trading session. During the trading session, ANIX stock reached the peak price of $3.42 while $3.28 was the lowest point it dropped to. The percentage change in ANIX stock occurred in the recent session was 2.12% while the dollar amount for the price change in ANIX stock was $0.07.

ANIX's industry and sector of operation?

The NASDAQ listed ANIX is part of Biotechnology industry that operates in the broader Healthcare sector. Anixa Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ANIX?

Dr. Pamela D. Garzone Ph.D.
Chief Devel. Officer & Chair Breast Cancer Clinical Advisory Board
Dr. Amit Kumar Ph.D.
Chairman & Chief Executive Officer
Mr. Michael J. Catelani CPA, MBA
Pres, Chief Operating Officer, Chief Financial Officer & Corporation Sec.
Mr. John Roop
Senior Vice President of Engineering

How ANIX did perform over past 52-week?

ANIX's closing price is 59.42% higher than its 52-week low of $2.07 where as its distance from 52-week high of $5.46 is -39.56%.

How many employees does ANIX have?

Number of ANIX employees currently stands at 5.

Link for ANIX official website?

Official Website of ANIX is: https://www.anixa.com

How do I contact ANIX?

ANIX could be contacted at phone 408 708 9808 and can also be accessed through its website. ANIX operates from 3150 Almaden Expressway, San Jose, CA 95118, United States.

How many shares of ANIX are traded daily?

ANIX stock volume for the day was 106.79K shares. The average number of ANIX shares traded daily for last 3 months was 318.05K.

What is the market cap of ANIX currently?

The market value of ANIX currently stands at $110.92M with its latest stock price at $3.37 and 32.91M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	5
Beta	0.5
Sales or Revenue	$0.00
5Y Sales Change%	-0.893%
Fiscal Year Ends	October
Sector	Healthcare
Industry	Biotechnology

ANIX Company Profile and Key Details

Anixa Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics